CD9 and neoplasm: The reduction in size in both primary tumours and metastases suggest an impairment of tumour cell growth, which was confirmed by Ki67 staining in histological sections from tumours treated with CD9 peptide and in a lesser extent with CD63 peptide (Figure 5f).